Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00119457|
Recruitment Status : Completed
First Posted : July 13, 2005
Last Update Posted : June 3, 2009
|Condition or disease||Intervention/treatment||Phase|
|Venous Thromboembolism Embolism and Thrombosis Hip Fractures||Drug: TTP889||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis With Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Following Hip Fracture Surgery|
|Study Start Date :||January 2005|
|Study Completion Date :||April 2006|
- To evaluate the antithrombotic efficacy of TTP889, administered once daily for three weeks, in patients who have completed standard prophylactic treatment for deep vein thrombosis after hip fracture surgery.
- Evaluation of safety of once daily oral administration of TTP889 for three weeks
- To assess the correlation between peak and trough plasma concentrations of TTP889 and clinical safety and efficacy outcomes.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00119457
|Study Chair:||Bengt I Eriksson, MD||Dept of Orthopaedics, Goteborg University|
|Study Director:||David P Ward, MD||vTv Therapeutics|